B. Riley analyst Dave Kang raised the firm’s price target on Viavi (VIAV) to $12 from $10 and keeps a Neutral rating on the shares. The company’s “lengthy downturn could finally be coming to an end based on its solid print and outlook,” the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.